

**Remarks**

Claims 1-7 are pending. No claims have been amended, added, or canceled by way of this Amendment. Amendment of the specification is requested as indicated. No new matter has been added.

The Office has required restriction among the pending claims as follows:

Group I, claim(s) 7 drawn to a composition.

Group II, claim(s) 1-6, drawn to a method of using the invention of Group I where R<sup>1</sup> is a carbocycle.


Group III, claim(s) 1-6, drawn to a method of using the invention of Group I where R<sup>1</sup> is a heterocycle.

Group IV, claim(s) 1-6, drawn to a method of using the invention of Group I where R<sup>1</sup> is a noncyclic.

Applicant elects without traverse Group I (claim 7), drawn to the recited composition. Applicants reserve the right to file one or more divisional applications to the non-elected subject matter.

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to effect the timely filing of this paper, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392. The Examiner is invited to contact the undersigned at (919) 483-8160, to discuss this case, if desired.

Respectfully submitted,



J. Scott Young  
Attorney for Applicants  
Reg. No. 45,582

Date: June 9 2008  
GlaxoSmithKline Inc.  
Five Moore Drive, PO Box 13398  
Research Triangle Park, NC 27709  
(919) 483-8160  
fax: (919) 483-7988  
Scott.S.Young@GSK.com